Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Income" stands at 17.56 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Novartis AG's third quarter result of 4.50 Billion USD for the item "Operating Income" represents a decrease of -7.46 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 4.50 Billion USD for the item "Operating Income" represents an increase of 24.10 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 17.56 Billion USD for the item "Operating Income" represents an increase of 5.24 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 29.14 percent compared to the value the year prior.
The 1 year change in percent is 29.14.
The 3 year change in percent is 85.45.
The 5 year change in percent is 88.17.
The 10 year change in percent is 81.93.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Income | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Income | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Income | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Income | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Income | 280,205,508,085.11 |